Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Common Equity (2020 - 2025)

Bolt Biotherapeutics' Common Equity history spans 6 years, with the latest figure at $32.1 million for Q3 2025.

  • For Q3 2025, Common Equity fell 55.43% year-over-year to $32.1 million; the TTM value through Sep 2025 reached $32.1 million, down 55.43%, while the annual FY2024 figure was $57.2 million, 49.27% down from the prior year.
  • Common Equity for Q3 2025 was $32.1 million at Bolt Biotherapeutics, down from $38.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $303.2 million in Q1 2021 and bottomed at $32.1 million in Q3 2025.
  • The 5-year median for Common Equity is $142.1 million (2023), against an average of $152.5 million.
  • The largest annual shift saw Common Equity soared 659.24% in 2021 before it tumbled 55.43% in 2025.
  • A 5-year view of Common Equity shows it stood at $250.1 million in 2021, then crashed by 31.43% to $171.5 million in 2022, then plummeted by 34.26% to $112.7 million in 2023, then crashed by 49.27% to $57.2 million in 2024, then tumbled by 43.88% to $32.1 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Common Equity are $32.1 million (Q3 2025), $38.8 million (Q2 2025), and $46.8 million (Q1 2025).